
Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer
A statistically significant overall survival (OS) improvement occurred among patients with hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer harboring PIK3CA mutations following treatment with inavolisib (Itovebi) plus …